# OnCo record nct03744468 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03744468/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03744468", "NCT03744468" ;
  schema:name "Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Alcestobart run by BeiGene, completed."@en ;
  schema:url <https://onco.cc/trials/nct03744468/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03744468> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/alcestobart/> ;
  onco:companies <https://onco.cc/companies/nanjing-leads-biolabs/> .